Fulcrum Therapeutics (FULC) Total Non-Current Liabilities (2019 - 2025)
Historic Total Non-Current Liabilities for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $16.3 million.
- Fulcrum Therapeutics' Total Non-Current Liabilities fell 2427.97% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year decrease of 2427.97%. This contributed to the annual value of $17.5 million for FY2024, which is 2159.7% down from last year.
- Fulcrum Therapeutics' Total Non-Current Liabilities amounted to $16.3 million in Q3 2025, which was down 2427.97% from $14.3 million recorded in Q2 2025.
- Over the past 5 years, Fulcrum Therapeutics' Total Non-Current Liabilities peaked at $34.3 million during Q2 2022, and registered a low of $14.0 million during Q1 2025.
- Over the past 5 years, Fulcrum Therapeutics' median Total Non-Current Liabilities value was $22.3 million (recorded in 2023), while the average stood at $21.9 million.
- Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 1741.19% in 2022, then plummeted by 2963.15% in 2025.
- Fulcrum Therapeutics' Total Non-Current Liabilities (Quarter) stood at $23.5 million in 2021, then grew by 17.41% to $27.5 million in 2022, then fell by 19.03% to $22.3 million in 2023, then fell by 21.6% to $17.5 million in 2024, then decreased by 6.82% to $16.3 million in 2025.
- Its last three reported values are $16.3 million in Q3 2025, $14.3 million for Q2 2025, and $14.0 million during Q1 2025.